Efficacy Evaluation and Cutaneous Acceptibility of a Dermocosmetic Product on Subjects Suffering of Atopic Dermatisis.

Inclusion Criteria:

Specific

• Sex: female and/or male;

• Age: from 3 months up to 12 years old;

• Phototype: I to IV;

• 100% with atopic skin;

• 100% with sensitive skin;

• Subject who had at least 3 eczema flares-up of atopic dermatitis during the last 6months before start of the study, including the crisis observed on D-X.

• Subject presenting on the visit D-X a flare-up of eczema for which the dermatologistprescribed treatment with topical corticosteroids treatment;

• Subjects with SCORAD between 15 and 40 on D-X;

• Subject who do not require medical treatment anymore after using prescribed topicalcorticosteroids from D-X up to D0 and clinical signs of atopic dermatitis areresolved, to be defined on D0 visit (in case of insufficient healing of inflammatorylesions, the subject continues medical treatment as recommended by theinvestigator).

General

• Healthy subject;

• Child whose at least one parent/legal guardian has given freely and expresslyher/his informed consent;

• Child whose at least one parent/legal guardian is willing to adhere to the protocoland study procedures;

• Polish citizenship.

Exclusion Criteria:

• Cutaneous pathology on the study zone other than atopic dermatitis;

• Use of topical or systemic treatment during the previous weeks liable to interferewith the assessment of the efficacy of the study products, including anti-histaminictreatment (except prescribed dermocorticoids on D-X and in case of flare-up duringthe study course);

• Subject having undergone a surgery under general anesthesia within the previousmonth;

• Excessive exposure to sunlight or UV-rays within the previous month;

• Subject enrolled in another clinical trial during the study period (concerns thestudied zones);

• Subjects presenting oozing eczema lesions or any sign of infection on eczema lesions (e.g; pus).